GlassScriptPhysician profile
Yen Pham
NPI 1083902613
$7,125.08
in general payments reported to CMS, 2019-2025
39 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61.17 · 2022: $2,122 · 2023: $2,360 · 2024: $1,318 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,941.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $971.51 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Novo Nordisk INC | $577.28 | 2022-2025 | Wegovy |
| Glaxosmithkline, LLC. | $455.24 | 2021-2025 | Pediarix, Bexsero, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $436.93 | 2022-2024 | Relistor, Xifaxan, Trulance |
| Abbvie INC. | $360.68 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $342.22 | 2022-2023 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $246.93 | 2023-2025 | Koselugo |
| Phathom Pharmaceuticals, INC. | $235.86 | 2024-2025 | Voquezna |
| Genzyme Corporation | $233.62 | 2024-2025 | |
| Amgen INC. | $199.45 | 2022-2023 | Repatha |
| Sanofi Pasteur INC. | $196.45 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $189.52 | 2021-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Corium, LLC | $164.04 | 2023-2024 | Azstarys |
| Abbott Laboratories | $154.26 | 2022 | |
| Scynexis, INC. | $138.00 | 2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yen Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.